Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Adjuvant therapy for esophageal cancer

Joshua E. Meyer • 20 Jan 2021
ASCO GI 2021
Esophageal Cancer Gastrointestinal Cancer

Joshua E. Meyer, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the role of adjuvant cytotoxic therapy for esophageal cancer, This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Joshua E. Meyer

Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer 3:05
Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer
Joshua E. Meyer • 20 Jan 2021
Novel approaches in the treatment of GI malignancies 1:39
Novel approaches in the treatment of GI malignancies
Joshua E. Meyer • 20 Jan 2021

Related Videos

Which patients with colorectal cancer will benefit the most from nivolumab? 1:21
Which patients with colorectal cancer will benefit the most from nivolumab?
Heinz-Josef Lenz • 31 May 2025
ASCO 2025 colorectal cancer updates: BREAKWATER & ATOMIC 1:31
ASCO 2025 colorectal cancer updates: BREAKWATER & ATOMIC
Heinz-Josef Lenz • 31 May 2025
AI for gastric cancer treatment prediction and guidance 0:49
AI for gastric cancer treatment prediction and guidance
Hyung-Don Kim • 31 May 2025
Targeting GSK-3ß with elraglusib in pancreatic cancer 1:43
Targeting GSK-3ß with elraglusib in pancreatic cancer
Devalingam Mahalingam • 1 Jun 2025
The content of VJOncology is intended for healthcare professionals